{"id":"control-insulin-novorapid","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin aspart is a genetically engineered insulin analog with a single amino acid substitution that allows faster absorption and onset of action compared to human insulin. It mimics the body's natural insulin response by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This rapid action makes it suitable for mealtime glucose control in diabetes management.","oneSentence":"Insulin aspart (NovoRapid) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:41.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06948760","phase":"NA","title":"Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D","status":"COMPLETED","sponsor":"Mark D. DeBoer, MD, MSc., MCR","startDate":"2025-07-23","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT05799781","phase":"NA","title":"Two Way Crossover Closed Loop MPC vs Control IQ","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2023-03-13","conditions":"Type 1 Diabetes","enrollment":29},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT05069545","phase":"","title":"A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-10-11","conditions":"Diabetes Mellitus, Type 1","enrollment":411},{"nctId":"NCT06547619","phase":"EARLY_PHASE1","title":"Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2024-10-01","conditions":"Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity","enrollment":40},{"nctId":"NCT04848480","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 1","enrollment":582},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT02054429","phase":"PHASE1","title":"Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2013-01","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT05946785","phase":"EARLY_PHASE1","title":"Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-07-01","conditions":"Gestational Diabetes, Vascular Endothelial Function","enrollment":28},{"nctId":"NCT05946798","phase":"EARLY_PHASE1","title":"Role of NADPH Oxidase in Microvascular Dysfunction Following GDM","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-08-30","conditions":"Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function","enrollment":40},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06199505","phase":"PHASE2","title":"A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-11-21","conditions":"Type 2 Diabetes","enrollment":153},{"nctId":"NCT05653050","phase":"NA","title":"Closing the Loop in People with Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2023-02-20","conditions":"Type 1 Diabetes","enrollment":26},{"nctId":"NCT05218915","phase":"PHASE4","title":"Basal Plus GLP1-ra on Glycemic Variability in CKD","status":"COMPLETED","sponsor":"Elaine Chow","startDate":"2022-01-28","conditions":"Diabetes Mellitus, Diabetic Kidney Disease","enrollment":95},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT06558708","phase":"PHASE2","title":"A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2024-06-28","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06532461","phase":"NA","title":"A Trial of Three- and Seven-days Insulin Infusions Set","status":"RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2024-07-20","conditions":"Type 1 Diabetes","enrollment":80},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT03660553","phase":"PHASE4","title":"Simplified Insulin Regimen for the Elderly","status":"TERMINATED","sponsor":"University of Miami","startDate":"2018-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":7},{"nctId":"NCT06127433","phase":"PHASE4","title":"The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-07","conditions":"Insulin Pump，Continuous Glucose Monitoring Technology","enrollment":210},{"nctId":"NCT00267683","phase":"PHASE3","title":"Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2005-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT05199714","phase":"NA","title":"A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-02-21","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT03770767","phase":"PHASE3","title":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Pregnancy Complications","enrollment":216},{"nctId":"NCT03387787","phase":"PHASE2, PHASE3","title":"Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-01-30","conditions":"Type 2 Diabetes Mellitus","enrollment":15},{"nctId":"NCT04243629","phase":"NA","title":"Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes","status":"UNKNOWN","sponsor":"McGill University","startDate":"2021-11-12","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia","enrollment":26},{"nctId":"NCT04759144","phase":"NA","title":"FASter Insulin in Closed-loop Technology in Children","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2021-03-12","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT03262116","phase":"PHASE2, PHASE3","title":"Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-03-19","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT05641337","phase":"PHASE3","title":"Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-10-01","conditions":"Liver Cirrhosis, Diabetes","enrollment":184},{"nctId":"NCT03689374","phase":"PHASE3","title":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":2274},{"nctId":"NCT04163874","phase":"NA","title":"Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-02-14","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial","enrollment":36},{"nctId":"NCT03579615","phase":"NA","title":"Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2020-12-23","conditions":"Diabetes Mellitus, Type 1","enrollment":18},{"nctId":"NCT04949867","phase":"PHASE4","title":"Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2021-05-20","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT04053712","phase":"PHASE4","title":"Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2019-07-16","conditions":"Type 1 Diabetes, Hypoglycemia","enrollment":13},{"nctId":"NCT05221359","phase":"NA","title":"Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes","status":"RECRUITING","sponsor":"Defymed","startDate":"2022-05-05","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia","enrollment":8},{"nctId":"NCT04141423","phase":"PHASE1","title":"Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil","status":"TERMINATED","sponsor":"Biocon Limited","startDate":"2019-10-28","conditions":"Type 1 Diabetes Mellitus (T1DM)","enrollment":55},{"nctId":"NCT00771693","phase":"PHASE4","title":"Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus, Postprandial Hyperglycemia","enrollment":18},{"nctId":"NCT03234491","phase":"PHASE1","title":"Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-11-22","conditions":"Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia","enrollment":15},{"nctId":"NCT03202875","phase":"PHASE1","title":"A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11-14","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT03336528","phase":"PHASE4","title":"Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-01-02","conditions":"Type 2 Diabetes","enrollment":180},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT03143816","phase":"PHASE4","title":"Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-09-30","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT04031599","phase":"NA","title":"Assessment of the Efficacy of the Artificial Pancreas Combined With a Qualitative Meal Size Estimation to Control Postprandial Glucose Levels","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2020-07-10","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT04834362","phase":"PHASE4","title":"Insulin for Hyperglycemia in Stroke Trial","status":"COMPLETED","sponsor":"National Institute of Neurosciences and Hospital, Dhaka","startDate":"2021-04-05","conditions":"Hyperglycemia, Stroke, Acute","enrollment":452},{"nctId":"NCT04292535","phase":"PHASE2","title":"Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2018-06-15","conditions":"Insulin, Exercise","enrollment":116},{"nctId":"NCT03800875","phase":"PHASE2","title":"Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting","status":"COMPLETED","sponsor":"McGill University","startDate":"2019-02-08","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT01654120","phase":"PHASE4","title":"Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics","status":"COMPLETED","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2011-12","conditions":"Diabetes Mellitus, Type II","enrollment":37},{"nctId":"NCT04409587","phase":"PHASE4","title":"Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump","status":"COMPLETED","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2018-04-12","conditions":"Type1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT04726657","phase":"NA","title":"Comparison of Two Biphasic Insulin Regimens","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2016-01-18","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT00461331","phase":"PHASE4","title":"Comparison of Insulins Aspart and Lispro in Insulin Pumps","status":"COMPLETED","sponsor":"Tulane University Health Sciences Center","startDate":"2004-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT00700154","phase":"NA","title":"Insulin Infusion Diabetes Ulcer","status":"TERMINATED","sponsor":"Karolinska Institutet","startDate":"2011-11","conditions":"Diabetes Mellitus, Insulin Resistance, Hyperglycemia","enrollment":40},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT01643382","phase":"NA","title":"Hyperglycemia in Renal Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-08","conditions":"Diabetes, End Stage Renal Disease","enrollment":60},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT00700362","phase":"","title":"Insulin Infusion and Infectious Diabetic Foot Ulcers (IIIFU)","status":"WITHDRAWN","sponsor":"Karolinska Institutet","startDate":"2011-12","conditions":"Diabetes Mellitus, Insulin Resistance, Hyperglycemia","enrollment":""},{"nctId":"NCT03977727","phase":"PHASE3","title":"FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump","status":"COMPLETED","sponsor":"Texas Diabetes & Endocrinology, P.A.","startDate":"2019-06-11","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT04055480","phase":"NA","title":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2019-08-10","conditions":"Type 1 Diabetes","enrollment":25},{"nctId":"NCT02846831","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-01-24","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT04222348","phase":"PHASE3","title":"MeDiGes Study: Metformine Use in Gestational Diabetes","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2016-10-26","conditions":"Diabetes, Gestational, Perinatal Disorder, Puerperal Disorder","enrollment":200},{"nctId":"NCT03450863","phase":"","title":"Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-03-22","conditions":"Diabetes, Diabetes Mellitus, Type 1 Diabetes","enrollment":320},{"nctId":"NCT00821795","phase":"PHASE4","title":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy","status":"COMPLETED","sponsor":"Dennis G. Karounos, M.D.","startDate":"2009-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT02814123","phase":"PHASE2","title":"Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University","startDate":"2017-01-13","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01684943","phase":"NA","title":"Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-07","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT01933490","phase":"NA","title":"Post-Gastric Bypass Hypoglycemia","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2013-08","conditions":"Hyperinsulinemic Hypoglycemia","enrollment":10},{"nctId":"NCT02590016","phase":"PHASE4","title":"Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Tampere University Hospital","startDate":"2015-09","conditions":"Gestational Diabetes, Hypoglycemia, Neonatal","enrollment":50},{"nctId":"NCT01966978","phase":"PHASE4","title":"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-11","conditions":"Diabetes Mellitus, Type 2, Diabetes","enrollment":157},{"nctId":"NCT02824510","phase":"NA","title":"Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2014-08","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT03565666","phase":"PHASE2, PHASE3","title":"The Insulin-Only Bionic Pancreas Bridging Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-07-09","conditions":"Type1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT02846857","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02582242","phase":"PHASE4","title":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-19","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":437},{"nctId":"NCT01513590","phase":"PHASE3","title":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":394},{"nctId":"NCT02004366","phase":"PHASE4","title":"Linagliptin Inpatient Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":295},{"nctId":"NCT02855307","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2016-09","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT03824002","phase":"PHASE4","title":"Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2017-04-01","conditions":"Diabetes Mellitus","enrollment":92},{"nctId":"NCT00906529","phase":"PHASE4","title":"Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-05","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT02449603","phase":"PHASE4","title":"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT01774565","phase":"NA","title":"Closed-loop Insulin Delivery in the General Ward","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2016-08","conditions":"Diabetes Mellitus","enrollment":43},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT02328040","phase":"PHASE1","title":"Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2014-09","conditions":"Diabetes Mellitus, Type 1","enrollment":17},{"nctId":"NCT02509429","phase":"PHASE2","title":"Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-06-16","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT03101865","phase":"NA","title":"The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01)","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2017-08-08","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00417989","phase":"NA","title":"Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2007-01","conditions":"Type 1 Diabetes","enrollment":485},{"nctId":"NCT03335501","phase":"PHASE2","title":"Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-04-01","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02488616","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-03","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT03212950","phase":"NA","title":"Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2017-07-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["First generation insulin analog"],"phase":"phase_3","status":"active","brandName":"Control (insulin Novorapid)","genericName":"Control (insulin Novorapid)","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin aspart (NovoRapid) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}